selected publications
- Pregnancy Outcomes and All-Cause Mortality After Pregnancy Among US-Born Women With Perinatally Acquired HIV. Journal of acquired immune deficiency syndromes (1999). 2025 Academic Article GET IT
- National Institutes of Health COVID-19 Treatment Guidelines Panel: Perspectives and Lessons Learned. Annals of internal medicine. 2024 Academic Article GET IT
- Pharmacologic Drug Detection and Self-Reported Adherence in the HPTN069/ACTG5305 Phase II PrEP Trial. AIDS and behavior. 2024 Academic Article GET IT
- Long-acting HIV Treatments: Study Design, Logistics, and Access. Open forum infectious diseases. 2024 Review GET IT
- Expectations of preventative benefits and risk behaviors in a randomized trial evaluating oral HIV preexposure prophylaxis candidates. AIDS care. 2024 Academic Article GET IT
- Lymphocyte Count Derived Polygenic Score and Interindividual Variability in CD4 T-cell Recovery in Response to Antiretroviral Therapy. Pacific Symposium on Biocomputing. Pacific Symposium on Biocomputing. 2024 Academic Article GET IT
- Influence of Participant Perceptions of Adherence-Related Interactions with Study/Study Team on Drug Levels: HPTN069 Analysis of Self-Reported Adherence Experiences While on Study. AIDS and behavior. 2023 Academic Article GET IT
- COVID-19. Annals of internal medicine. 2023 Review GET IT
- Lessons from COVID-19 for Pandemic Preparedness: Proceedings from a Multi-Stakeholder Think Tank. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2023 Academic Article GET IT
- Mass spectrometry imaging of hair identifies daily maraviroc adherence in HPTN 069/ACTG A5305. PloS one. 2023 Academic Article GET IT
- Sexual behavior and medication adherence in men who have sex with men participating in a pre-exposure prophylaxis study of combinations of Maraviroc, Tenofovir Disoproxil Fumarate and/or Emtricitabine (HPTN 069/ACTG 5305). AIDS and behavior. 2022 Academic Article GET IT
- Bone changes with candidate PrEP regimens containing tenofovir disoproxil fumarate and/or maraviroc and/or emtricitabine in US men and women: HPTN 069/ACTG A5305. The Journal of antimicrobial chemotherapy. 2021 Academic Article GET IT
- Managing HIV Treatment Failure: Time to REVAMP?. Annals of internal medicine. 2021 Editorial Article GET IT
-
Selecting Treatments During an Infectious Disease Pandemic: Chasing the Evidence.
Annals of internal medicine.
2021
Academic Article
GET IT
Times cited: 5 -
Cabotegravir for HIV Prevention in Cisgender Men and Transgender Women.
The New England journal of medicine.
2021
Academic Article
GET IT
Times cited: 3 - Higher colorectal tissue HIV infectivity in cisgender women compared with MSM before and during oral preexposure prophylaxis. AIDS (London, England). 2021 Academic Article GET IT
-
HIV: Closing the Mortality Gap.
Annals of internal medicine.
2021
Editorial Article
GET IT
Times cited: 1 - Developing Treatment Guidelines During a Pandemic Health Crisis: Lessons Learned From COVID-19. Annals of internal medicine. 2021 Academic Article GET IT
- Tissue specificity-aware TWAS (TSA-TWAS) framework identifies novel associations with metabolic, immunologic, and virologic traits in HIV-positive adults. PLoS genetics. 2021 Academic Article GET IT
-
Antiretroviral drug activity and potential for pre-exposure prophylaxis against COVID-19 and HIV infection.
Journal of biomolecular structure & dynamics.
2021
Academic Article
GET IT
Times cited: 7 -
Failure of chronic hydroxychloroquine in preventing severe complications of COVID-19 in patients with rheumatic diseases.
Rheumatology advances in practice.
2021
Academic Article
GET IT
Times cited: 5 - Randomized Pilot Study of an Advanced Smart-Pill Bottle as an Adherence Intervention in Patients With HIV on Antiretroviral Treatment. Journal of acquired immune deficiency syndromes (1999). 2021 Academic Article GET IT
-
The Uncertain Role of Corticosteroids in the Treatment of COVID-19.
JAMA internal medicine.
2021
Letter
GET IT
Times cited: 2 -
Blood component utilization in COVID-19 patients in New York City: Transfusions do not follow the curve.
Transfusion.
2020
Academic Article
GET IT
Times cited: 20 -
Prioritizing clinical research studies during the COVID-19 pandemic: lessons from New York City.
The Journal of clinical investigation.
2020
Academic Article
GET IT
Times cited: 8 - Efavirenz Pharmacogenetics and Weight Gain following Switch to Integrase Inhibitor-containing Regimens. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2020 Academic Article GET IT
-
COVID-19 in Hospitalized Adults With HIV.
Open forum infectious diseases.
2020
Academic Article
GET IT
Times cited: 41 -
Safety, tolerability, and clinical outcomes of hydroxychloroquine for hospitalized patients with coronavirus 2019 disease.
PloS one.
2020
Academic Article
GET IT
Times cited: 16 -
Obesity and COVID-19 in New York City: A Retrospective Cohort Study.
Annals of internal medicine.
2020
Letter
GET IT
Times cited: 69 -
Severe Covid-19.
The New England journal of medicine.
2020
Review
GET IT
Times cited: 333 -
Clinical Characteristics of Covid-19 in New York City.
The New England journal of medicine.
2020
Letter
GET IT
Times cited: 1656 -
Prior Case of Resistance on Dolutegravir Plus Lamivudine Dual Therapy.
AIDS research and human retroviruses.
2020
Article
GET IT
Times cited: 2 -
HIV treatment and prevention 2019: current standards of care.
Current opinion in HIV and AIDS.
2020
Information Resource
GET IT
Times cited: 7 -
Comparable viral decay with initial dolutegravir plus lamivudine versus dolutegravir-based triple therapy.
The Journal of antimicrobial chemotherapy.
2019
Academic Article
GET IT
Times cited: 8 -
Dolutegravir plus lamivudine for initial treatment of HIV-1-infected participants with HIV-1 RNA <500 000 copies/mL: week 48 outcomes from ACTG 5353.
The Journal of antimicrobial chemotherapy.
2019
Academic Article
GET IT
Times cited: 20 -
Perspectives of US women participating in a candidate PrEP study: adherence, acceptability and future use intentions.
Journal of the International AIDS Society.
2019
Academic Article
GET IT
Times cited: 16 -
Racial Disparities in Virologic Failure and Tolerability During Firstline HIV Antiretroviral Therapy.
Open forum infectious diseases.
2019
Academic Article
GET IT
Times cited: 7 -
The pharmacokinetics, pharmacodynamics, and mucosal responses to maraviroc-containing pre-exposure prophylaxis regimens in MSM.
AIDS (London, England).
2019
Academic Article
GET IT
Times cited: 18 -
No change in health-related quality of life for at-risk U.S. women and men starting HIV pre-exposure prophylaxis (PrEP): Findings from HPTN 069/ACTG A5305.
PloS one.
2018
Academic Article
GET IT
Times cited: 4 -
The Control of HIV After Antiretroviral Medication Pause (CHAMP) Study: Posttreatment Controllers Identified From 14 Clinical Studies.
The Journal of infectious diseases.
2018
Academic Article
GET IT
Times cited: 134 -
Long-Acting HIV Drugs for Treatment and Prevention.
Annual review of medicine.
2018
Information Resource
GET IT
Times cited: 41 -
Combination therapy with anti-HIV-1 antibodies maintains viral suppression.
Nature.
2018
Academic Article
GET IT
Times cited: 367 -
Safety and antiviral activity of combination HIV-1 broadly neutralizing antibodies in viremic individuals.
Nature medicine.
2018
Academic Article
GET IT
Times cited: 186 -
Relationship between latent and rebound viruses in a clinical trial of anti-HIV-1 antibody 3BNC117.
The Journal of experimental medicine.
2018
Academic Article
GET IT
Times cited: 82 -
Brain neurotransmitter transporter/receptor genomics and efavirenz central nervous system adverse events.
Pharmacogenetics and genomics.
2018
Academic Article
GET IT
Times cited: 5 -
ACTG A5353: A Pilot Study of Dolutegravir Plus Lamivudine for Initial Treatment of Human Immunodeficiency Virus-1 (HIV-1)-infected Participants With HIV-1 RNA <500000 Copies/mL.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
2018
Academic Article
GET IT
Times cited: 84 -
Investigational Antiretroviral Drugs: What is Coming Down the Pipeline.
Topics in antiviral medicine.
2018
Academic Article
GET IT
Times cited: 24 -
Genetic Variation of the Kinases That Phosphorylate Tenofovir and Emtricitabine in Peripheral Blood Mononuclear Cells.
AIDS research and human retroviruses.
2018
Academic Article
GET IT
Times cited: 12 - A Conversation Among the IAS-USA Board of Directors: Hot Topics and Emerging Data in HIV Research and Care. Topics in antiviral medicine. 2017 Academic Article GET IT
-
Race/Ethnicity and the Pharmacogenetics of Reported Suicidality With Efavirenz Among Clinical Trials Participants.
The Journal of infectious diseases.
2017
Academic Article
GET IT
Times cited: 23 -
Safety and Tolerability of Maraviroc-Containing Regimens to Prevent HIV Infection in Women: A Phase 2 Randomized Trial.
Annals of internal medicine.
2017
Academic Article
GET IT
Times cited: 30 -
Antibody 10-1074 suppresses viremia in HIV-1-infected individuals.
Nature medicine.
2017
Academic Article
GET IT
Times cited: 371 -
Phase 2 Study of the Safety and Tolerability of Maraviroc-Containing Regimens to Prevent HIV Infection in Men Who Have Sex With Men (HPTN 069/ACTG A5305).
The Journal of infectious diseases.
2017
Academic Article
GET IT
Times cited: 43 - Invasive Aspergillus Sinusitis in Human Immunodeficiency Virus Infection: Case Report and Review of the Literature. Open forum infectious diseases. 2016 Information Resource GET IT
-
HIV-1 antibody 3BNC117 suppresses viral rebound in humans during treatment interruption.
Nature.
2016
Academic Article
GET IT
Times cited: 377 -
Cost-Effectiveness of Meningococcal Vaccination Among Men Who Have Sex With Men in New York City.
Journal of acquired immune deficiency syndromes (1999).
2016
Academic Article
GET IT
Times cited: 4 -
The Cost-effectiveness and Budget Impact of 2-Drug Dolutegravir-Lamivudine Regimens for the Treatment of HIV Infection in the United States.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
2015
Academic Article
GET IT
Times cited: 56 -
Virologic and immunologic effects of adding maraviroc to suppressive antiretroviral therapy in individuals with suboptimal CD4+ T-cell recovery.
AIDS (London, England).
2015
Academic Article
GET IT
Times cited: 21 -
Viraemia suppressed in HIV-1-infected humans by broadly neutralizing antibody 3BNC117.
Nature.
2015
Academic Article
GET IT
Times cited: 628 -
Phenome-wide Association Study Relating Pretreatment Laboratory Parameters With Human Genetic Variants in AIDS Clinical Trials Group Protocols.
Open forum infectious diseases.
2015
Academic Article
GET IT
Times cited: 31 - HIV treatment 2020: what will it look like?. Journal of the International AIDS Society. 2014 Academic Article GET IT
-
Association between efavirenz as initial therapy for HIV-1 infection and increased risk for suicidal ideation or attempted or completed suicide: an analysis of trial data.
Annals of internal medicine.
2014
Academic Article
GET IT
Times cited: 170 -
Genome-Wide Association Study of Human Immunodeficiency Virus (HIV)-1 Coreceptor Usage in Treatment-Naive Patients from An AIDS Clinical Trials Group Study.
Open forum infectious diseases.
2014
Academic Article
GET IT
Times cited: 5 -
Antiretroviral therapy and efficacy after virologic failure on first-line boosted protease inhibitor regimens.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
2014
Academic Article
GET IT
Times cited: 12 -
Regulatory T cells and the risk of CMV end-organ disease in patients with AIDS.
Journal of acquired immune deficiency syndromes (1999).
2014
Academic Article
GET IT
Times cited: 12 -
Associations of inflammatory markers with AIDS and non-AIDS clinical events after initiation of antiretroviral therapy: AIDS clinical trials group A5224s, a substudy of ACTG A5202.
Journal of acquired immune deficiency syndromes (1999).
2014
Academic Article
GET IT
Times cited: 61 -
Five-year safety evaluation of maraviroc in HIV-1-infected treatment-experienced patients.
Journal of acquired immune deficiency syndromes (1999).
2014
Academic Article
GET IT
Times cited: 39 -
Outcomes among HIV-1 infected individuals first starting antiretroviral therapy with concurrent active TB or other AIDS-defining disease.
PloS one.
2013
Academic Article
GET IT
Times cited: 2 -
Outcomes by sex following treatment initiation with atazanavir plus ritonavir or efavirenz with abacavir/lamivudine or tenofovir/emtricitabine.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
2013
Academic Article
GET IT
Times cited: 29 -
Racial differences in response to antiretroviral therapy for HIV infection: an AIDS clinical trials group (ACTG) study analysis.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
2013
Academic Article
GET IT
Times cited: 39 -
Weight and lean body mass change with antiretroviral initiation and impact on bone mineral density.
AIDS (London, England).
2013
Academic Article
GET IT
Times cited: 43 -
Modeling clinical endpoints as a function of time of switch to second-line ART with incomplete data on switching times.
Biometrics.
2013
Academic Article
GET IT
Times cited: 5 -
Anthropometric differences between HIV-infected individuals prior to antiretroviral treatment and the general population from 1998-2007: the AIDS Clinical Trials Group Longitudinal Linked Randomized Trials (ALLRT) cohort and NHANES.
PloS one.
2013
Academic Article
GET IT
Times cited: 4 -
Changes in HIV-1 subtypes B and C genital tract RNA in women and men after initiation of antiretroviral therapy.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
2013
Academic Article
GET IT
Times cited: 19 -
Early virologic response to abacavir/lamivudine and tenofovir/emtricitabine during ACTG A5202.
HIV clinical trials.
2013
Academic Article
GET IT
Times cited: 3 -
Genome-wide association study of plasma efavirenz pharmacokinetics in AIDS Clinical Trials Group protocols implicates several CYP2B6 variants.
Pharmacogenetics and genomics.
2012
Academic Article
GET IT
Times cited: 124 -
Changes in fat mitochondrial DNA and function in subjects randomized to abacavir-lamivudine or tenofovir DF-emtricitabine with atazanavir-ritonavir or efavirenz: AIDS Clinical Trials Group study A5224s, substudy of A5202.
The Journal of infectious diseases.
2012
Academic Article
GET IT
Times cited: 45 -
HIV-1 amino acid changes among participants with virologic failure: associations with first-line efavirenz or atazanavir plus ritonavir and disease status.
The Journal of infectious diseases.
2012
Academic Article
GET IT
Times cited: 18 -
Impact of UGT1A1 Gilbert variant on discontinuation of ritonavir-boosted atazanavir in AIDS Clinical Trials Group Study A5202.
The Journal of infectious diseases.
2012
Academic Article
GET IT
Times cited: 24 -
Next-generation oral preexposure prophylaxis: beyond tenofovir.
Current opinion in HIV and AIDS.
2012
Information Resource
GET IT
Times cited: 28 -
Efficacy and safety of three antiretroviral regimens for initial treatment of HIV-1: a randomized clinical trial in diverse multinational settings.
PLoS medicine.
2012
Academic Article
GET IT
Times cited: 107 - Evaluating the Effect of Early Versus Late ARV Regimen Change if Failure on an Initial Regimen: Results From the AIDS Clinical Trials Group Study A5095. Journal of the American Statistical Association. 2012 Academic Article GET IT
-
Inflammation markers after randomization to abacavir/lamivudine or tenofovir/emtricitabine with efavirenz or atazanavir/ritonavir.
AIDS (London, England).
2012
Academic Article
GET IT
Times cited: 90 -
A pilot trial of adding maraviroc to suppressive antiretroviral therapy for suboptimal CD4⁺ T-cell recovery despite sustained virologic suppression: ACTG A5256.
The Journal of infectious diseases.
2012
Academic Article
GET IT
Times cited: 66 -
Virologic, clinical and immunologic responses following failure of first-line antiretroviral therapy in Haiti.
Journal of the International AIDS Society.
2012
Academic Article
GET IT
Times cited: 23 -
Novel clinical trial designs for the development of new antiretroviral agents.
AIDS (London, England).
2012
Information Resource
GET IT
Times cited: 18 -
Vicriviroc resistance decay and relative replicative fitness in HIV-1 clinical isolates under sequential drug selection pressures.
Journal of virology.
2012
Academic Article
GET IT
Times cited: 9 -
CD28-negative CD4+ and CD8+ T cells in antiretroviral therapy-naive HIV-infected adults enrolled in adult clinical trials group studies.
The Journal of infectious diseases.
2012
Academic Article
GET IT
Times cited: 36 -
Quality of life among individuals with HIV starting antiretroviral therapy in diverse resource-limited areas of the world.
AIDS and behavior.
2012
Academic Article
GET IT
Times cited: 38 -
Differential use of CCR5 by HIV-1 clinical isolates resistant to small-molecule CCR5 antagonists.
Antimicrobial agents and chemotherapy.
2012
Academic Article
GET IT
Times cited: 8 -
Cost-effectiveness of adding an agent that improves immune responses to initial antiretroviral therapy (ART) in HIV-infected patients: guidance for drug development.
HIV clinical trials.
2012
Academic Article
GET IT
Times cited: 7 -
HIV-1 clinical isolates resistant to CCR5 antagonists exhibit delayed entry kinetics that are corrected in the presence of drug.
Journal of virology.
2011
Academic Article
GET IT
Times cited: 27 -
Comparative effectiveness of initial antiretroviral therapy regimens: ACTG 5095 and 5142 clinical trials relative to ART-CC cohort study.
Journal of acquired immune deficiency syndromes (1999).
2011
Academic Article
GET IT
Times cited: 20 -
CCR5 antagonism in HIV infection: current concepts and future opportunities.
Annual review of medicine.
2011
Information Resource
GET IT
Times cited: 62 -
Peripheral and central fat changes in subjects randomized to abacavir-lamivudine or tenofovir-emtricitabine with atazanavir-ritonavir or efavirenz: ACTG Study A5224s.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
2011
Academic Article
GET IT
Times cited: 104 -
Bone mineral density and fractures in antiretroviral-naive persons randomized to receive abacavir-lamivudine or tenofovir disoproxil fumarate-emtricitabine along with efavirenz or atazanavir-ritonavir: Aids Clinical Trials Group A5224s, a substudy of ACTG A5202.
The Journal of infectious diseases.
2011
Academic Article
GET IT
Times cited: 428 -
Incidence of non-AIDS-defining cancer in antiretroviral treatment-naïve subjects after antiretroviral treatment initiation: an ACTG longitudinal linked randomized trials analysis.
Oncology.
2011
Academic Article
GET IT
Times cited: 36 -
Peripheral neuropathy in HIV: prevalence and risk factors.
AIDS (London, England).
2011
Academic Article
GET IT
Times cited: 157 -
No risk of myocardial infarction associated with initial antiretroviral treatment containing abacavir: short and long-term results from ACTG A5001/ALLRT.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
2011
Academic Article
GET IT
Times cited: 129 -
Reanalysis of coreceptor tropism in HIV-1-infected adults using a phenotypic assay with enhanced sensitivity.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
2011
Academic Article
GET IT
Times cited: 42 -
Episomal viral cDNAs identify a reservoir that fuels viral rebound after treatment interruption and that contributes to treatment failure.
PLoS pathogens.
2011
Academic Article
GET IT
Times cited: 67 -
Incidence rate of and factors associated with loss to follow-up in a longitudinal cohort of antiretroviral-treated HIV-infected persons: an AIDS Clinical Trials Group (ACTG) Longitudinal Linked Randomized Trials (ALLRT) analysis.
HIV clinical trials.
2011
Academic Article
GET IT
Times cited: 32 -
Sex-associated differences in pre-antiretroviral therapy plasma HIV-1 RNA in diverse areas of the world vary by CD4(+) T-cell count.
Antiviral therapy.
2011
Academic Article
GET IT
Times cited: 27 -
Two-year safety and virologic efficacy of maraviroc in treatment-experienced patients with CCR5-tropic HIV-1 infection: 96-week combined analysis of MOTIVATE 1 and 2.
Journal of acquired immune deficiency syndromes (1999).
2010
Academic Article
GET IT
Times cited: 83 -
Change in high-sensitivity c-reactive protein levels following initiation of efavirenz-based antiretroviral regimens in HIV-infected individuals.
AIDS research and human retroviruses.
2010
Academic Article
GET IT
Times cited: 26 -
The major genetic determinants of HIV-1 control affect HLA class I peptide presentation.
Science (New York, N.Y.).
2010
Academic Article
GET IT
Times cited: 978 -
Comparisons of anemia, thrombocytopenia, and neutropenia at initiation of HIV antiretroviral therapy in Africa, Asia, and the Americas.
International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases.
2010
Academic Article
GET IT
Times cited: 57 -
Effect of CYP2B6, ABCB1, and CYP3A5 polymorphisms on efavirenz pharmacokinetics and treatment response: an AIDS Clinical Trials Group study.
The Journal of infectious diseases.
2010
Academic Article
GET IT
Times cited: 126 -
Switching from efavirenz to nevirapine.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
2010
Letter
GET IT
Times cited: 5 -
Three-year safety and efficacy of vicriviroc, a CCR5 antagonist, in HIV-1-infected treatment-experienced patients.
Journal of acquired immune deficiency syndromes (1999).
2010
Academic Article
GET IT
Times cited: 25 -
Early versus standard antiretroviral therapy for HIV-infected adults in Haiti.
The New England journal of medicine.
2010
Academic Article
GET IT
Times cited: 325 -
Measurement of naive CD4 cells reliably predicts potential for immune reconstitution in HIV.
Journal of acquired immune deficiency syndromes (1999).
2010
Academic Article
GET IT
Times cited: 27 -
Pharmacokinetic/pharmacodynamic modeling of the antiretroviral activity of the CCR5 antagonist Vicriviroc in treatment experienced HIV-infected subjects (ACTG protocol 5211).
Journal of acquired immune deficiency syndromes (1999).
2010
Academic Article
GET IT
Times cited: 8 -
Pre-existing minority drug-resistant HIV-1 variants, adherence, and risk of antiretroviral treatment failure.
The Journal of infectious diseases.
2010
Academic Article
GET IT
Times cited: 183 -
Substitution of nevirapine because of efavirenz toxicity in AIDS clinical trials group A5095.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
2010
Academic Article
GET IT
Times cited: 27 -
A randomized, placebo-controlled trial of abacavir intensification in HIV-1-infected adults with virologic suppression on a protease inhibitor-containing regimen.
HIV clinical trials.
2010
Academic Article
GET IT
Times cited: 18 -
Vicriviroc and peripheral neuropathy: results from AIDS Clinical Trials Group 5211.
HIV clinical trials.
2010
Academic Article
GET IT
Times cited: 4 -
Response to vicriviroc in treatment-experienced subjects, as determined by an enhanced-sensitivity coreceptor tropism assay: reanalysis of AIDS clinical trials group A5211.
The Journal of infectious diseases.
2009
Academic Article
GET IT
Times cited: 49 -
Long-term impact of efavirenz on neuropsychological performance and symptoms in HIV-infected individuals (ACTG 5097s).
HIV clinical trials.
2009
Academic Article
GET IT
Times cited: 89 -
HLA-associated immune escape pathways in HIV-1 subtype B Gag, Pol and Nef proteins.
PloS one.
2009
Academic Article
GET IT
Times cited: 147 -
Proteinuria, creatinine clearance, and immune activation in antiretroviral-naive HIV-infected subjects.
The Journal of infectious diseases.
2009
Academic Article
GET IT
Times cited: 23 -
Assessing human immunodeficiency virus type 1 tropism: Comparison of assays using replication-competent virus versus plasma-derived pseudotyped virions.
Journal of clinical microbiology.
2009
Academic Article
GET IT
Times cited: 6 -
Quantitative deep sequencing reveals dynamic HIV-1 escape and large population shifts during CCR5 antagonist therapy in vivo.
PloS one.
2009
Academic Article
GET IT
Times cited: 185 -
Uncertainty as to whether the use of antiretroviral therapy for persons recently infected with HIV has a favorable risk-to-benefit ratio.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
2009
Letter
GET IT
Times cited: 5 -
Lymphoma diagnosis and plasma Epstein-Barr virus load during vicriviroc therapy: results of the AIDS Clinical Trials Group A5211.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
2009
Academic Article
GET IT
Times cited: 17 -
When to start antiretroviral therapy?.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
2008
Information Resource
GET IT
Times cited: 21 -
Survival, plasma HIV-1 RNA concentrations and drug resistance in HIV-1-infected Haitian adolescents and young adults on antiretrovirals.
Bulletin of the World Health Organization.
2008
Academic Article
GET IT
Times cited: 35 -
Maraviroc for previously treated patients with R5 HIV-1 infection.
The New England journal of medicine.
2008
Academic Article
GET IT
Times cited: 678 -
Detection of nonnucleoside reverse-transcriptase inhibitor-resistant HIV-1 after discontinuation of virologically suppressive antiretroviral therapy.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
2008
Academic Article
GET IT
Times cited: 28 -
In vivo emergence of vicriviroc resistance in a human immunodeficiency virus type 1 subtype C-infected subject.
Journal of virology.
2008
Academic Article
GET IT
Times cited: 104 -
Class-sparing regimens for initial treatment of HIV-1 infection.
The New England journal of medicine.
2008
Academic Article
GET IT
Times cited: 631 -
Genotypic susceptibility scores and HIV type 1 RNA responses in treatment-experienced subjects with HIV type 1 infection.
AIDS research and human retroviruses.
2008
Academic Article
GET IT
Times cited: 26 -
Efavirenz-based regimens in treatment-naive patients with a range of pretreatment HIV-1 RNA levels and CD4 cell counts.
The Journal of infectious diseases.
2008
Academic Article
GET IT
Times cited: 15 -
Preexisting resistance to nonnucleoside reverse-transcriptase inhibitors predicts virologic failure of an efavirenz-based regimen in treatment-naive HIV-1-infected subjects.
The Journal of infectious diseases.
2008
Academic Article
GET IT
Times cited: 129 -
Randomized study of dual versus single ritonavir-enhanced protease inhibitors for protease inhibitor-experienced patients with HIV.
HIV clinical trials.
2008
Academic Article
GET IT
Times cited: 8 -
Seven-year efficacy of a lopinavir/ritonavir-based regimen in antiretroviral-naïve HIV-1-infected patients.
HIV clinical trials.
2008
Academic Article
GET IT
Times cited: 70 -
Racial differences in virologic failure associated with adherence and quality of life on efavirenz-containing regimens for initial HIV therapy: results of ACTG A5095.
Journal of acquired immune deficiency syndromes (1999).
2007
Academic Article
GET IT
Times cited: 59 -
A comparison of three initial antiretroviral AIDS regimens.
The New England journal of medicine.
2007
Article
GET IT
Times cited: 5 -
Phase 2 study of the safety and efficacy of vicriviroc, a CCR5 inhibitor, in HIV-1-Infected, treatment-experienced patients: AIDS clinical trials group 5211.
The Journal of infectious diseases.
2007
Academic Article
GET IT
Times cited: 221 - New antiretroviral agents. Current infectious disease reports. 2007 Academic Article GET IT
-
Intensification of a triple-nucleoside regimen with tenofovir or efavirenz in HIV-1-infected patients with virological suppression.
AIDS (London, England).
2007
Academic Article
GET IT
Times cited: 20 -
Metabolic effects of protease inhibitor-sparing antiretroviral regimens given as initial treatment of HIV-1 Infection (AIDS Clinical Trials Group Study A5095).
Journal of acquired immune deficiency syndromes (1999).
2007
Academic Article
GET IT
Times cited: 46 -
Plasma HIV-1 RNA dynamics in antiretroviral-naive subjects receiving either triple-nucleoside or efavirenz-containing regimens: ACTG A5166s.
The Journal of infectious diseases.
2007
Academic Article
GET IT
Times cited: 36 -
Non-nucleoside phenotypic hypersusceptibility cut-point determination from ACTG 359.
HIV clinical trials.
2007
Academic Article
GET IT
Times cited: 2 -
Evidence of ongoing immune reconstitution in subjects with sustained viral suppression following 6 years of lopinavir-ritonavir treatment.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
2007
Academic Article
GET IT
Times cited: 36 -
HIV type 1 chemokine coreceptor use among antiretroviral-experienced patients screened for a clinical trial of a CCR5 inhibitor: AIDS Clinical Trial Group A5211.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
2007
Academic Article
GET IT
Times cited: 155 -
A randomized trial of treatment interruption before optimized antiretroviral therapy for persons with drug-resistant HIV: 48-week virologic results of ACTG A5086.
The Journal of infectious diseases.
2006
Academic Article
GET IT
Times cited: 18 -
Three- vs four-drug antiretroviral regimens for the initial treatment of HIV-1 infection: a randomized controlled trial.
JAMA.
2006
Academic Article
GET IT
Times cited: 197 -
Switching antiretroviral therapy: why, when and how.
IAPAC monthly.
2006
Academic Article
GET IT
Times cited: 2 -
Design issues in initial HIV-treatment trials: focus on ACTG A5095.
Antiviral therapy.
2006
Academic Article
GET IT
Times cited: 11 -
Pharmacogenetics of plasma efavirenz exposure after treatment discontinuation: an Adult AIDS Clinical Trials Group Study.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
2005
Academic Article
GET IT
Times cited: 178 -
Antiretroviral therapy in a thousand patients with AIDS in Haiti.
The New England journal of medicine.
2005
Academic Article
GET IT
Times cited: 231 -
Impact of efavirenz on neuropsychological performance and symptoms in HIV-infected individuals.
Annals of internal medicine.
2005
Academic Article
GET IT
Times cited: 215 -
Histological findings and clinical characteristics associated with hepatic steatosis in patients coinfected with HIV and hepatitis C virus.
The Journal of infectious diseases.
2005
Academic Article
GET IT
Times cited: 74 -
Four measures of antiretroviral medication adherence and virologic response in AIDS clinical trials group study 359.
Journal of acquired immune deficiency syndromes (1999).
2005
Academic Article
GET IT
Times cited: 43 -
The neuropsychological and neurological impact of hepatitis C virus co-infection in HIV-infected subjects.
AIDS (London, England).
2005
Academic Article
GET IT
Times cited: 54 -
Accuracy, precision, and consistency of expert HIV type 1 genotype interpretation: an international comparison (The GUESS Study).
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
2005
Academic Article
GET IT
Times cited: 7 -
Antiretroviral therapies for treatment-experienced patients: current status and research challenges.
AIDS (London, England).
2005
Editorial Article
GET IT
Times cited: 47 -
Pharmacogenetics of efavirenz and central nervous system side effects: an Adult AIDS Clinical Trials Group study.
AIDS (London, England).
2004
Academic Article
GET IT
Times cited: 532 -
Case-control study of diabetes mellitus in HIV-infected patients.
Journal of acquired immune deficiency syndromes (1999).
2004
Academic Article
GET IT
Times cited: 24 -
Activity, safety, and immunological effects of hydroxyurea added to didanosine in antiretroviral-naive and experienced HIV type 1-infected subjects: a randomized, placebo-controlled trial, ACTG 307.
AIDS research and human retroviruses.
2004
Academic Article
GET IT
Times cited: 21 - New Antiretroviral Agents for the Treatment of HIV Infection. Current infectious disease reports. 2004 Academic Article GET IT
-
Weighted phenotypic susceptibility scores are predictive of the HIV-1 RNA response in protease inhibitor-experienced HIV-1-infected subjects.
The Journal of infectious diseases.
2004
Academic Article
GET IT
Times cited: 24 -
New antiretroviral agents for the treatment of HIV infection.
Current HIV/AIDS reports.
2004
Information Resource
GET IT
Times cited: 6 -
Triple-nucleoside regimens versus efavirenz-containing regimens for the initial treatment of HIV-1 infection.
The New England journal of medicine.
2004
Academic Article
GET IT
Times cited: 463 -
Long-term safety and durable antiretroviral activity of lopinavir/ritonavir in treatment-naive patients: 4 year follow-up study.
AIDS (London, England).
2004
Academic Article
GET IT
Times cited: 109 -
Sex-based differences in saquinavir pharmacology and virologic response in AIDS Clinical Trials Group Study 359.
The Journal of infectious diseases.
2004
Academic Article
GET IT
Times cited: 81 -
Short-term safety and antiretroviral activity of T-1249, a second-generation fusion inhibitor of HIV.
The Journal of infectious diseases.
2004
Academic Article
GET IT
Times cited: 120 -
Six-year follow-up of HIV-1-infected adults in a clinical trial of antiretroviral therapy with indinavir, zidovudine, and lamivudine.
AIDS (London, England).
2003
Academic Article
GET IT
Times cited: 50 - Antiretroviral Therapy: When and What to Start-- An American Perspective. Current infectious disease reports. 2003 Academic Article GET IT
-
A randomized trial to study first-line combination therapy with or without a protease inhibitor in HIV-1-infected patients.
AIDS (London, England).
2003
Academic Article
GET IT
Times cited: 174 -
Brief report: efficacy and treatment-limiting toxicity with the concurrent use of lopinavir/ritonavir and a third protease inhibitor in treatment-experienced HIV-infected patients.
Journal of acquired immune deficiency syndromes (1999).
2003
Academic Article
GET IT
Times cited: 10 -
New antiretroviral drugs.
Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.
2003
Information Resource
GET IT
Times cited: 98 -
Analysis of virological efficacy in trials of antiretroviral regimens: drawbacks of not including viral load measurements after premature discontinuation of therapy.
Antiviral therapy.
2002
Academic Article
GET IT
Times cited: 19 -
Durability of response to treatment among antiretroviral-experienced subjects: 48-week results from AIDS Clinical Trials Group Protocol 359.
The Journal of infectious diseases.
2002
Academic Article
GET IT
Times cited: 11 -
Dual vs single protease inhibitor therapy following antiretroviral treatment failure: a randomized trial.
JAMA.
2002
Academic Article
GET IT
Times cited: 160 -
The pharmacokinetics of amprenavir, zidovudine, and lamivudine in the genital tracts of men infected with human immunodeficiency virus type 1 (AIDS clinical trials group study 850).
The Journal of infectious diseases.
2002
Academic Article
GET IT
Times cited: 37 -
Safety and antiviral activity at 48 weeks of lopinavir/ritonavir plus nevirapine and 2 nucleoside reverse-transcriptase inhibitors in human immunodeficiency virus type 1-infected protease inhibitor-experienced patients.
The Journal of infectious diseases.
2002
Academic Article
GET IT
Times cited: 142 -
New drugs for HIV therapy.
AIDS (London, England).
2002
Information Resource
GET IT
Times cited: 5 -
Structured treatment interruption in patients infected with HIV: a new approach to therapy.
Drugs.
2002
Information Resource
GET IT
Times cited: 34 - Treatment sequencing: use protease inhibitors first. IAPAC sessions 2001, July 18-19, 2001 - Chicago. IAPAC monthly. 2001 Conference Paper GET IT
-
Effect of ritonavir/saquinavir on stereoselective pharmacokinetics of methadone: results of AIDS Clinical Trials Group (ACTG) 401.
Journal of acquired immune deficiency syndromes (1999).
2001
Academic Article
GET IT
Times cited: 74 -
Patterns of plasma human immunodeficiency virus type 1 RNA response to antiretroviral therapy.
The Journal of infectious diseases.
2001
Academic Article
GET IT
Times cited: 42 -
Residual human immunodeficiency virus (HIV) Type 1 RNA and DNA in lymph nodes and HIV RNA in genital secretions and in cerebrospinal fluid after suppression of viremia for 2 years.
The Journal of infectious diseases.
2001
Academic Article
GET IT
Times cited: 121 - New Drugs for the Treatment of HIV Infection. Current infectious disease reports. 2001 Academic Article GET IT
-
Indinavir, nevirapine, stavudine, and lamivudine for human immunodeficiency virus-infected, amprenavir-experienced subjects: AIDS Clinical Trials Group protocol 373.
The Journal of infectious diseases.
2001
Academic Article
GET IT
Times cited: 13 -
ABT-378/ritonavir plus stavudine and lamivudine for the treatment of antiretroviral-naive adults with HIV-1 infection: 48-week results.
AIDS (London, England).
2001
Academic Article
GET IT
Times cited: 221 -
Competing drug-drug interactions among multidrug antiretroviral regimens used in the treatment of HIV- infected subjects: ACTG 884.
AIDS (London, England).
2000
Academic Article
GET IT
Times cited: 45 -
Randomized study of saquinavir with ritonavir or nelfinavir together with delavirdine, adefovir, or both in human immunodeficiency virus-infected adults with virologic failure on indinavir: AIDS Clinical Trials Group Study 359.
The Journal of infectious diseases.
2000
Academic Article
GET IT
Times cited: 85 -
Assessing the benefits of antiretroviral therapy.
Annals of internal medicine.
2000
Editorial Article
GET IT
Times cited: 10 -
A comparison of stavudine plus lamivudine versus zidovudine plus lamivudine in combination with indinavir in antiretroviral naive individuals with HIV infection: selection of thymidine analog regimen therapy (START I).
AIDS (London, England).
2000
Academic Article
GET IT
Times cited: 86 -
3-year suppression of HIV viremia with indinavir, zidovudine, and lamivudine.
Annals of internal medicine.
2000
Academic Article
GET IT
Times cited: 179 -
The effects of protease inhibitor therapy on human immunodeficiency virus type 1 levels in semen (AIDS clinical trials group protocol 850).
The Journal of infectious diseases.
2000
Academic Article
GET IT
Times cited: 65 - Salvage therapy. AIDS clinical care. 1999 Article GET IT
-
Treatment with amprenavir alone or amprenavir with zidovudine and lamivudine in adults with human immunodeficiency virus infection. AIDS Clinical Trials Group 347 Study Team.
The Journal of infectious diseases.
1999
Academic Article
GET IT
Times cited: 78 -
Phase I studies of hypericin, the active compound in St. John's Wort, as an antiretroviral agent in HIV-infected adults. AIDS Clinical Trials Group Protocols 150 and 258.
Annals of internal medicine.
1999
Academic Article
GET IT
Times cited: 94 -
Antiviral activity of the human immunodeficiency virus type 1-specific nonnucleoside reverse transcriptase inhibitor HBY 097 alone and in combination with zidovudine in a phase II study. HBY 097/2001 Study Group.
The Journal of infectious diseases.
1999
Academic Article
GET IT
Times cited: 14 -
Rethinking nonadherence: historical perspectives on triple-drug therapy for HIV disease.
Annals of internal medicine.
1998
Information Resource
GET IT
Times cited: 125 - Antiretroviral therapy; where are we going?. AIDS patient care and STDs. 1998 Editorial Article GET IT
-
Simultaneous vs sequential initiation of therapy with indinavir, zidovudine, and lamivudine for HIV-1 infection: 100-week follow-up.
JAMA.
1998
Academic Article
GET IT
Times cited: 218 -
HIV treatment strategies: planning for the long term.
JAMA.
1998
Editorial Article
GET IT
Times cited: 19 -
Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy.
The New England journal of medicine.
1997
Academic Article
GET IT
Times cited: 1653 -
Recombinant, truncated CD4 molecule (rT4) binds IgG.
Journal of immunology (Baltimore, Md. : 1950).
1990
Academic Article
GET IT
Times cited: 9 -
Dextran sulfate and heparin interact with CD4 molecules to inhibit the binding of coat protein (gp120) of HIV.
Journal of immunology (Baltimore, Md. : 1950).
1989
Academic Article
GET IT
Times cited: 102